TRIM56 and metabolic dysfunction-associated steatotic liver disease: In addition, AI-assisted drug discovery yielded the identification of a small-molecule inhibitor of FASN, FASstatin, which boosted TRIM56-FASN interaction and increased TRIM56-driven FASN degradation and thus ameliorated NAFLD pathologies in mice with good efficacy, safety, and pharmacokinetics profiles.